All In Biotech

Drug Trial Radar · NCT07901842

Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence

Intravenous Recombinant Human Prourokinase for Extended-Window Acute Ischemic Stroke Selected by NCCT-Based Artificial Intelligence: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 826 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

826

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Dec 1, 2029

Study completion Jun 1, 2030

Sponsor

Sponsor type
Academic, hospital or other
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, prospective, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in patients with acute ischemic stroke treated more than 4.5 hours and up to 24 hours after stroke onset, selected using a noncontrast computed tomography-based artificial intelligence (CT-AI) tissue-window algorithm. A total of 826 participants will be randomly assigned in a 1:1 ratio to receive intravenous rhPro-UK or matching placebo, in addition to guideline-recommended standard stroke care. The primary outcome is the proportion of participants achieving a modified Rankin Scale (mRS) score of 0-1 at 90 ± 7 days. Secondary outcomes include functional outcomes, changes in neurological deficits, early neurological improvement at 24 hours and 7 days, and tissue reperfusion at 24-48 hours. Safety outcomes include symptomatic intracranial hemorrhage, parenchymal hematoma, all-cause mortality, and serious systemic bleeding.

Conditions

  • Acute Ischemic Stroke

Interventions

  • Recombinant Human Prourokinase for Injection (rhPro-UK)Drug

    A total dose of 35 mg will be administered intravenously. The initial 15 mg dissolved in 10 mL solution will be administered by intravenous bolus over 3 minutes, followed by 20 mg dissolved in 90 mL solution administered by intravenous infusion over 30 minutes.

  • Matching Placebo for Recombinant Human ProurokinaseDrug

    Matching placebo will be administered intravenously using the same administration volumes, route, and durations as the active study drug to maintain blinding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants With a Modified Rankin Scale Score of 0-1 at 90 DaysTime frame: 90 ± 7 days after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Neurology, the Second Affiliated Hospital of Zhejiang University, School of Medicine

    Hangzhou, Zhengjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.